Stamford, Conn.-based Loxo Oncology Inc. and partner Bayer AG, of Leverkusen, Germany, recently scored their expected win with the accelerated clearance by the FDA for Vitrakvi (larotrectinib) to treat adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation.